Summary
Millions of Medicare beneficiaries struggling with obesity may soon see the cost of weight-loss drugs plummet, as a new federal pilot program launching July 1 expands access to GLP-1 medications like Wegovy and Zepbound for eligible seniors. The program, Medicare GLP-1 Bridge, offers a selection of brand-name medications for $50 a month, a significant reduction from the previous cost of $1,350-$1,650 per month. The program is set to run until the end of 2027 and is the first time GLP-1s will be covered by insurance when used solely for weight loss.
Our Reading
The advice sounds familiar. This guidance has been heard before, as the Medicare GLP-1 Bridge program enters another phase in the ongoing discussion about weight loss and medication coverage. The program’s temporary nature and the fact that it is the first time GLP-1s will be covered by insurance when used solely for weight loss raise questions about the long-term implications of this decision. The program’s focus on eligible seniors and the requirement that they have had a body mass index (BMI) of 35 or higher when they started GLP-1 therapy, or a BMI of 27 or higher alongside another health condition, highlight the complexity of the issue. The fact that older patients tend to have more adverse effects to medication in general adds another layer of consideration.
Author: Evan Null
